4DMedical Ltd. (OTC: FDMDF | ASX: 4DX) 

4DMedical is an Australian-based medical technology company, commercialising four-dimensional lung imaging solutions.

4DMedical was incorporated in 2012 to acquire imaging platform, XV Technology™, and associated intellectual property, from Monash University where it was originally conceived in 2005 and developed by CEO, Andreas Fouras, and his former research group.

4DMedical’s XV Technology™ is the first FDA cleared respiratory imaging solution that utilises mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data. XV Technology™ is the result of over 15 years of development and published preclinical and clinical studies. The technology has been extensively patented, with core patents granted in key jurisdictions including the United States and Australia.

4DMedical considers its market opportunity to be supplementing or replacing existing respiratory diagnostic modalities. In 2019, more than US$31 billion was spent on respiratory diagnostics across more than 377 million procedures globally.

Sona Nanotech Inc. (OTCQB: SNANF | CSE: SONA) 

Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, that uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion, an approach aligned with the melanoma research community's active focus on converting immunogenically 'cold' tumors, which resist immunotherapy, into 'hot' tumors that the immune system can recognize and attack, thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

Raphael Pharmaceutical (OTCQB: RAPH)

We are a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids. We collaborate with world-class research experts to harness the power of rigorous scientific methods and advanced technologies to develop safe, effective cannabinoidbased formulas. Our most advanced development candidates include novel, patentable formulations designed to treat rheumatoid arthritis (lead candidate), chronic lung inflammation and autoimmune disease. 

Adaptin Bio, Inc. (OTCQB: APTN) 

Adaptin Bio, is a pioneering biotechnology company dedicated to revolutionizing drug delivery. Our focus is on developing innovative technologies that enhance how medications and other therapeutic compounds reach their target destinations within the body.

Our core mission is to overcome a major hurdle in medicine: ensuring effective delivery of drugs to specific tissues.

Many critical medications and diagnostic tools struggle to reach the areas where they can have the most significant impact. The blood-brain barrier that protects the central nervous system being the most famous example.

Adaptin Bio's precision medicine technologies are designed to address this challenge. We are creating methods to deliver drugs and other compounds directly to their target sites, maximizing their effectiveness and minimizing potential side effects. 

CytoDyn Inc. (OTCQB: CYDY) 

CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments utilizing leronlimab, a novel humanized monoclonal antibody that targets the CCR5 receptor. Leronlimab is being studied for its paradigm-shifting potential in solid-tumor oncology. The Company also strategically works with select partners to explore leronlimab’s potential benefits in certain inflammatory diseases. CytoDyn is committed to enhancing the lives of patients. Additional information about our Company and our development pipeline can be viewed at the links below. 

Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX)  

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). 

Avicanna Inc. (OTCQX: AVCNF | TSX: AVCN)   

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products. with a focus on the medical and pharmaceutical market segments at an international level, Avicanna has established an industry leading scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. 

Altrova Health Inc. (OTCQB: ATVHF | CSE: ROVA)

Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) is a Canadian public company building a growing portfolio of health solutions across detection, protection, treatment, and wellness. The Company's current product portfolio includes exclusive Canadian distribution rights for the NIRLAB SA ("NIRLAB") NIRLIGHT drug analysis device, the ToxiShield fentanyl and drink-spiking detection product line, and the O-Spray product line, alongside the rapid detection strip portfolio of its subsidiary Drug Lab 118 Ltd.